Medical devices, healthcare technology and the business of care
510(k) clearance · K260049

Elecsys Anti-HBc IgM

Roche Diagnostics · Decision date Apr 7, 2026

FDA DECISIONK260049

What did the FDA decide?

FDA records K260049 as a 510(k) premarket notification, with a decision dated Apr 7, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Apr 7, 2026

FDA source record

Regulatory record facts

Identifier
K260049
Regulatory pathway
510(k) premarket notification
Product code
SEI
Decision code
SESE
Decision date
Apr 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Qualitative And Quantitative Hepatitis B Virus Antibody Assays.

Product code
SEI
FDA device class
2

FDA decision timeline

  1. K260049 received

    Application receipt date recorded by FDA.

  2. K260049 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code SEI

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Diagnostics510(k) clearanceApr 7, 2026FDA
BECKMAN COULTER, INC.510(k) clearanceMar 13, 2026FDA
BECKMAN COULTER, INC.510(k) clearanceFeb 19, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Diagnostics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Indianapolis, IN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records